Amplia Therapeutics Ltd

ATX

Company Profile

  • Business description

    Amplia Therapeutics Ltd is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. Its molecule, AMP945 is a pure-play inhibitor, while the second molecule, AMP886, is a multi-action molecule that hits two other important cancer pathways: VEGFR3 and FLT3.

  • Contact

    350 Queen Street
    Level 17
    MelbourneVIC3000
    AUS

    T: +61 391231140

    https://www.ampliatx.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 March 2026

    Employees

Stocks News & Analysis

stocks

Our top ASX picks in every sector

These companies are our top choices for investors wanting to boost Aussie exposure.
stocks

Potentially catastrophic ruling for ASX company

We raise our risk and uncertainty rating to reflect the impact of the ruling.
stocks

4 charts on Nvidia’s record $4 trillion market cap

Shares of the semiconductor giant have rocketed 280% over the past two years amid the AI boom.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,875.3060.000.68%
CAC 407,820.8812.710.16%
DAX 4024,204.9444.300.18%
Dow JONES (US)44,459.6588.140.20%
FTSE 1008,997.700.36-0.00%
HKSE24,590.12386.801.60%
NASDAQ20,640.3354.800.27%
Nikkei 22539,678.02218.400.55%
NZX 50 Index12,689.6310.940.09%
S&P 5006,268.568.810.14%
S&P/ASX 2008,630.3059.900.70%
SSE Composite Index3,505.0014.65-0.42%

Market Movers